GPT and metabolic dysfunction-associated steatotic liver disease: This finding is consistent with other publications, where for example, in the assessment of liver fibrosis in individuals with a diagnosis of non-alcoholic fatty liver disease only 11% had the necessary measures to allow the assessment of FIB-4 in the UK (rising to 54% in Catalonia, Spain).19 Furthermore, we found that <9% of abnormal ALT measurements also had an AST measured within a 6-week window.